The ECFS-CTN cannot guarantee that the information provided here is comprehensive. Please go to the ClinicalTrials.gov link for detailed and up-to-date information on study background, eligibility criteria, study design, outcome measures, study status, participating sites, sponsor contact information and timelines.
You can also contact the CTN coordinating centre for additional information: ECFS-CTN@uzleuven.be (link sends e-mail)
Study Name on ClinicalTrialsRegister.eu (link is external) | Trial of Optimal Therapy for Pseudomonas Eradication in Cystic Fibrosis |
---|---|
Study Drug | Ceftazidime, Tobramycin, Ciprofloxacin (This trial will assess whether ten days intravenous ceftazidime with tobramycin is superior to three months oral ciprofloxacin at eradicating P. aeruginosa from the lungs of Cystic Fibrosis patients. Both treatment regimes will be in conjunction with three months nebulised colistin) |
Type of Study Drug | Anti-infective |
Study Title | Trial of Optimal Therapy for Pseudomonas Eradication in Cystic Fibrosis |
Study Phase | 4 |
Study Sponsor | University Hospitals Bristol NHS Foundation Trust |
Link European Trials Register | https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012575-10/GB Additional information: |
Participating ECFS-CTN sites | Leeds, Birmingham, Nottingham, London |
Age | Children over the age of 28 days No upper age limitation |